Abstract
Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.
Highlights
Cancer is a dangerous illness and a public health concern
The release rates of drugs were 42% and 25% less, respectively, compared with those observed in the study of Huang et al, who prepared a glutathione (GSH) sensitive prodrug carrier and showed an 85% drug release from the hybrid system when used against ovarian cancer [58]
These findings indicate that the lipid shells and biodegradable polymeric core contribute to an effective nano-drug formulation based on core-shell hybrid NPs coated with folic acid (FA) for targeted anti-cancer therapy
Summary
Cancer is a dangerous illness and a public health concern. It can affect any organ in the body and is characterized by uncontrolled growth and division of abnormal cells. PLHNPs often show distinct benefits compared with those of traditional drug carriers, such as improved physiological properties, favorable release kinetics, superior capability to encapsulate both hydrophilic and hydrophobic therapeutic drugs, enormous plasma stability, easy formulation with a range of lipids and biodegradable polymers, differences in structural configuration, longer circulation times, cellular and molecular recognition, and enhanced. Polymer‐lipid hybrid nanoparticles (PLHNPs) combine the advantages of both polymeric NPs and liposomes This hybrid system overcomes the limitations of lipids and polymers and offers enormous potential in the field of nanomedicine [26]. PLHNPs often show distinct benefits compared with those of traditional drug carriers, such as improved physiological properties, favorable release kinetics, superior capability to encapsulate both hydrophilic and hydrophobic therapeutic drugs, enormous plasma stability, easy with a range of lipids and biodegradable polymers, differences in structural. The different hybrid structures represent effective delivery systems compared with either of their
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
